Research To Practice | Oncology Videos

Latest Episodes:

Prostate Cancer | Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Prostate Cancer May 30, 2024

Show notes

Featuring perspectives from Dr Rahul Aggarwal, Dr Adam S Kibel, Dr Laurence Klotz and Dr Sandy Srinivas, moderated by Dr Elisabeth I Heath, including the following topics:

Introduction (0:00)
Recent Data Defining the Optimal Use of Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Kibel (2:39)
Side Effects and Other Practical Considerations with Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Klotz (27:04)
Current and Future Approaches to Hormonal Therapy for Metastatic Prostate Cancer — Dr Aggarwal (51:07)
New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Srinivas (1:13:53)
Other Novel Therapies for Patients with Metastatic Prostate Cancer — Dr Heath (1:38:52)

CME information and select publications

Lymphoma | Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences May 29, 2024

Show notes

Featuring perspectives from Dr Andrew D Zelenetz, including the following topics:

Follicular Lymphoma (0:00)
Mantle Cell Lymphoma (30:29)
Diffuse Large B-Cell Lymphoma (55:01)
Hodgkin Lymphoma (1:12:25)

CME information and select publications

Acute Lymphoblastic Leukemia | Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Companion Faculty Lecture) May 28, 2024

Show notes

Featuring a slide presentation and related discussion from Dr Elias Jabbour, including the following topics:

Clinical management of Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL); factors in the selection of initial induction treatment (0:00)
Primary and secondary endpoint outcomes from the Phase III PhALLCON trial comparing ponatinib to imatinib, each with reduced-intensity chemotherapy, as front-line treatment for Ph-positive ALL (5:22)
Efficacy and tolerability of ponatinib in combination with blinatumomab for patients with newly diagnosed Ph-positive ALL (17:04)
Ongoing research with novel agents and strategies for Ph-positive ALL (24:47)

CME information and select publications

Acute Lymphoblastic Leukemia | Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia May 28, 2024

Show notes

Featuring an interview with Dr Elias Jabbour, including the following topics:

Evolution of research and therapeutic options for acute lymphoblastic leukemia (ALL) (0:00)
Clinical and biological characteristics of ALL and implications for prognosis and disease management (6:36)
Case: A 48-year-old woman with newly diagnosed Philadelphia chromosome-positive (Ph-positive) ALL attains complete remission with ponatinib/blinatumomab (14:03)
Tolerability and improved quality of life with the chemotherapy-free combination of ponatinib and blinatumomab (24:17)
Case: A 38-year-old man with newly diagnosed Ph-positive ALL experiences a complete molecular response with induction hyper-CVAD and ponatinib (27:10)

CME information and select publications

Multiple Myeloma | Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma (Companion Faculty Lecture) May 24, 2024

Show notes

Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics:

Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00)
Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46)
Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40)
Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26)
Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55)
Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39)

CME information and select publications

Multiple Myeloma | Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma May 24, 2024

Show notes

Featuring an interview with Dr Joshua Richter, including the following topics:

Management of cytokine release syndrome after bispecific antibody therapy; importance of clinical trials in the multiple myeloma (MM) treatment paradigm (0:00)
Similarities and differences between and efficacy and tolerability of BCMA- and non-BCMA-directed bispecific antibodies in the treatment of MM (7:18)
Case: A woman in her mid 60s with penta-refractory MM who achieves complete remission with linvoseltamab on a clinical trial (12:53)
Case: A woman in her early 60s with multiregimen-refractory MM who experiences pain and tumor flare during step-up dosing of teclistamab (22:40)
Case: A man in his late 60s with relapsed/refractory MM who experiences disease relapse 18 months after chimeric antigen receptor T-cell therapy begins treatment with talquetamab (28:34)
Racial and ethnic disparities in the treatment of MM (32:09)

CME information and select publications

Hepatobiliary Cancers | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Hepatobiliary Cancers May 23, 2024

Show notes

Featuring perspectives from Ms Blanca Ledezma, Dr Stacey Stein, Ms Amanda K Wagner and Dr Mark Yarchoan, including the following topics:

Introduction (0:00)
Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma (HCC) (9:40)
Role of Immunotherapy in Intermediate-Stage HCC (17:02)
First-Line Therapy for Advanced HCC (19:56)
Immunotherapy in the Management of Advanced Biliary Tract Cancers (BTCs) (44:29)
Biomarker Testing Recommendations and the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma (58:02)
Potential Role of HER2-Targeted Therapy for BTCs (1:17:16)

CME information and select publications

HER2-Positive Breast Cancer | Oncology Today with Dr Neil Love: Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer May 21, 2024

Show notes

Featuring perspectives from Dr Adam M Brufsky, including the following topics:

Review of Local Therapy (0:00)
Treatment Advances for HER2 Positive Early-Stage Breast Cancer (18:35)
Case: A woman in her early 60s with ER-positive, HER2-positive (IHC 3+) with infiltrating ductal carcinoma who received T-DM1 with an aromatase inhibitor (19:37)
Case: A woman in her early 50s with ER-positive, HER2-positive (IHC 3+) who received TCHP followed by a mastectomy (56:26)
Beyond the Guidelines Survey and HERRISK (1:02:23)
Trials in Progress (1:14:44)

CME information and select publications

Endometrial Cancer | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Endometrial Cancer May 18, 2024

Show notes

Featuring perspectives from Ms Jennifer Filipi, Ms Kathryn Lyle, Dr David O'Malley and Dr Shannon N Westin, including the following topics:

Introduction (0:00)
Incidence and Biology of Endometrial Cancer (EC) (9:30)
Use of Immune Checkpoint Inhibitors as Monotherapy for EC (23:24)
First-Line Therapy for Primary Advanced or Recurrent EC (28:28)
Lenvatinib/Pembrolizumab in the Management of Metastatic EC (1:05:08)
Potential Role of Selinexor in the Management of EC (1:13:20)
Incidence and Management of HER2-Positive EC (1:22:51)

NCPD information and select publications

Prostate Cancer | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Prostate Cancer May 16, 2024

Show notes

Featuring perspectives from Dr Andrew J Armstrong and Ms Brenda Martone, including the following topics:

Introduction: Overview of Prostate Cancer; Hormonal Therapy (0:00)
Radiopharmaceuticals for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) (24:11)
Biomarker Testing for mCRPC; PARP Inhibitors for mCRPC (49:33)

NCPD information and select publications